Karen Firestone Acquires 8,100 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Karen Firestone bought 8,100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the acquisition, the director directly owned 63,100 shares in the company, valued at $785,595. The trade was a 14.73% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $12.24 on Thursday. Amylyx Pharmaceuticals, Inc. has a one year low of $2.60 and a one year high of $16.96. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -6.80 and a beta of -0.34. The company has a fifty day moving average price of $13.64 and a two-hundred day moving average price of $10.80.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. Research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in Amylyx Pharmaceuticals by 7.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock valued at $7,090,000 after purchasing an additional 143,065 shares in the last quarter. Invesco Ltd. bought a new position in shares of Amylyx Pharmaceuticals in the 1st quarter valued at $162,000. Woodline Partners LP acquired a new position in shares of Amylyx Pharmaceuticals during the 1st quarter worth $5,697,000. American Century Companies Inc. lifted its position in shares of Amylyx Pharmaceuticals by 80.4% during the 1st quarter. American Century Companies Inc. now owns 107,014 shares of the company’s stock worth $379,000 after buying an additional 47,704 shares during the last quarter. Finally, Alpha Wave Global LP boosted its stake in Amylyx Pharmaceuticals by 47.3% in the second quarter. Alpha Wave Global LP now owns 275,842 shares of the company’s stock valued at $1,768,000 after buying an additional 88,531 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AMLX. Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Robert W. Baird boosted their price target on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Citigroup upped their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday, October 17th. HC Wainwright lifted their target price on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Bank of America boosted their target price on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.